Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.


Serum samples from 137 lung cancer patients were examined by RIA to evaluate the clinical efficacy of the new tumor marker, CYFRA 21-1, which could identify the soluble fragment of cytokeratin 19. The cut-off value was determined to be 2.2 ng/ml according to the receiver operating characteristic curve. The sensitivity, specificity and accuracy of the RIA… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.